YahooSeptember 12, 2026 at 3:40 AM NYLast Month
BridgeBio Oncology Therapeutics (BBOT) Bets Big On A Narrower KRAS Playbook
On September 8, BridgeBio Oncology Therapeutics (NASDAQ:BBOT) released new clinical data for its lead KRASG12C inhibitor, BBO-8520, and used the moment to narrow its focus: the company is now prioritizing BBO-8520 paired with a checkpoint inhibitor in previously treated lung cancer patients, alongside combination work for its two earlier-stage assets, BBO-11818 and BBO-10203, in other […]
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Yahoo
